LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

52.799

80.03

Aktsiakasum

1.18

Dividenditootlus

0.27

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.59% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.27%

2.29%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

612M

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

24%

76%

78 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. dets 2025, 20:41 UTC

Tulu
Suurimad hinnamuutused turgudel

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. dets 2025, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. dets 2025, 17:43 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. dets 2025, 17:01 UTC

Tulu

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. dets 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. dets 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. dets 2025, 21:37 UTC

Tulu

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. dets 2025, 21:36 UTC

Tulu

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. dets 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. dets 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. dets 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. dets 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. dets 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. dets 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. dets 2025, 16:33 UTC

Market Talk
Tulu

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

7.59% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  7.59%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

78 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat